#ADC

All articles tagged with "ADC"

Daiichi Sankyo Takes Nearly $1 Billion Hit After Pulling Back ADC Capacity Plans

Daiichi Sankyo said it is scrapping plans to build antibody-drug conjugate manufacturing capacity and recorded an extraordinary loss of 149.4 billion yen after overestimating demand, highlighting the risks of expanding

Key Takeaways

Daiichi Sankyo reported an extraordinary loss of 149.4 billion yen, roughly $950 million.
The loss was tied to overestimating demand for antibody-drug conjugate manufacturing capacity.

DT Editorial Team·May 11, 2026·via endpoints.news

Experimental ovarian cancer drug posts early signs of benefit in phase 1 trial

An investigational antibody-drug conjugate targeting CLDN6 showed clinical activity in heavily pretreated patients with advanced platinum-resistant ovarian cancer, according to phase 1 data presented at AACR 2026.

Key Takeaways

QLS5132 is an investigational ADC targeting CLDN6 in advanced platinum-resistant ovarian cancer.
In a 28-patient phase 1 study, adverse events were common but no treatment-related event caused discontinuation or death.

DT Editorial Team·Apr 20, 2026·via medicalxpress.com